No-Spa (Drotaverine Hydrochloride)

Drotaverine Hydrochloride, the active ingredient in No‑Spa, is an antispasmodic presented as a tablet for oral use. It acts by relaxing smooth muscle and is employed to relieve abdominal pain, menstrual cramps, biliary colic and other spasm‑related conditions in adult patients.

GNH USA supplies No‑Spa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards for consistent global distribution. The company provides regulatory documentation and supports import logistics for institutional buyers across multiple continents.

Drotaverine is an antispasmodic that relaxes smooth muscle in various organ systems. - Abdominal pain: alleviates cramping and discomfort associated with gastrointestinal spasm. - Menstrual cramps: reduces uterine muscle contractions to ease dysmenorrhea. - Biliary colic: relaxes biliary tract smooth muscle to relieve pain from gallstone obstruction. - Smooth muscle spasm: provides symptomatic relief in other visceral spasm conditions.

Drotaverine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild stomach upset. - Dizziness: transient light‑headedness. - Dry mouth: reduced salivation. - Headache: mild to moderate intensity. - Hypotension: occasional drop in blood pressure. - Taste alteration: metallic or bitter taste.

Serious or Rare Side Effects: - Allergic reaction: rash, itching or swelling. - Severe hypotension: marked blood pressure fall requiring medical attention. - Hepatic enzyme elevation: abnormal liver function tests. - Blood dyscrasias: neutropenia or thrombocytopenia. - Anaphylaxis: life‑threatening systemic allergic response.

When considering drotaverine therapy, several safety measures should be observed. - Pregnancy: use only if clearly needed and prescribed by a healthcare professional. - Breastfeeding: caution advised; assess risk‑benefit before use. - Renal impairment: monitor renal function and adjust therapy if necessary. - Elderly patients: start with the lowest effective dose and observe tolerance. - Concomitant medications: review all drugs for potential interactions before initiating therapy. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Drotaverine can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Other antispasmodics: combined use may increase risk of excessive smooth‑muscle relaxation and hypotension. - Potent CYP450 inhibitors (e.g., ketoconazole, erythromycin): may raise drotaverine plasma levels, enhancing side effects. - Antihistamines with sedative properties: additive central nervous system depression.

Moderate Interactions (Monitor Closely): - NSAIDs: concurrent use may increase gastrointestinal irritation. - Beta‑blockers: may potentiate blood‑pressure‑lowering effects. - Alcohol: can augment dizziness and hypotensive responses. - Diuretics: monitor electrolytes and blood pressure when used together.